Mainz Biomed Change in Accounts Receivable 2021-2024 | MYNZ

Mainz Biomed change in accounts receivable from 2021 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Mainz Biomed Change in Accounts Receivable 2021-2024 | MYNZ

Mainz Biomed change in accounts receivable from 2021 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$225.3B
Amgen (AMGN)$164.8B
Gilead Sciences (GILD)$144.5B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$98.6B
CSL (CSLLY)$85.4B
GSK (GSK)$77.7B
Regeneron Pharmaceuticals (REGN)$60.8B
Alnylam Pharmaceuticals (ALNY)$42.9B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.7B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.7B
Biogen (BIIB)$19.3B
Illumina (ILMN)$17.3B
Genmab (GMAB)$15B
Genmab (GNMSF)$15B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.4B
QIAGEN (QGEN)$11.5B
BioMarin Pharmaceutical (BMRN)$11.3B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.2B
Bio-Techne Corp (TECH)$9.2B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8B
Roivant Sciences (ROIV)$7.9B